Shandong Xinhua Pharmaceutical Receives Drug Registration Certificate for Valsartan Capsules
I'm PortAI, I can summarize articles.
Shandong Xinhua Pharmaceutical Company Limited has received a Drug Registration Certificate for its Valsartan Capsules from the National Medical Products Administration. This approval follows the company's application to the Center for Drug Evaluation in September 2024 and the completion of the review process in December 2025. No other organizations were mentioned in connection with this approval.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments